Sichuan Biokin Pharmaceutical Co.,Ltd. (688506.SH) has announced that the company recently received the official Drug Clinical Trial Approval Notice issued by the National Medical Products Administration (NMPA), granting approval for clinical trials of its independently developed innovative biologic drug, injectable BL-M12D1 (ADC).
Injectable BL-M12D1 is an ADC drug that originates from the same technology platform as iza-bren and shares the same "linker plus toxin" platform with Yizekang (lunconilimab, BL-B01D1/iza-bren). Its indication is relapsed or refractory hematological malignancies.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.